Stoke Therapeutics, Inc. STOK Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by Stoke Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The official record: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Stoke Therapeutics, Inc.'s other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Stoke Therapeutics, Inc.'s other income (expense)?
- Stoke Therapeutics, Inc. (STOK) reported other income (expense) of $3.42M in Q1 2026.
- How has Stoke Therapeutics, Inc.'s other income (expense) changed year-over-year?
- Stoke Therapeutics, Inc.'s other income (expense) increased by 17.1% year-over-year, from $2.92M to $3.42M.
- What is the long-term trend for Stoke Therapeutics, Inc.'s other income (expense)?
- Over 4 years (2021 to 2025), Stoke Therapeutics, Inc.'s other income (expense) has grown at a 169.4% compound annual growth rate (CAGR), from $260K to $13.71M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.